Plain-English translation of NCT07073833 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to previous treatments. The study is divided into two phases: first, researchers will test different doses of the medication alone to find the safest and most effective dose, then expand to test both the medication by itself and combined with another immunotherapy drug.
Many people with B-cell lymphoma eventually stop responding to standard treatments, leaving them with few options. This trial exists to see if this new cell-based treatment can help patients whose cancer has become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
The trial has two main phases. In the first phase, participants will receive increasing doses of the medication to determine the safest dose. In the second phase, some participants will receive the medication alone, while others will receive it combined with an anti-CD20 antibody drug. You will have regular visits for medical exams, blood tests, and imaging scans to monitor how you respond to the treatment and watch for any side effects.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China